Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group.

@article{Keeffe1999UtilityOH,
  title={Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group.},
  author={Emmet B. Keeffe and Geoffrey Dusheiko and Stephen P. James and Kevin Daniel Mullen and Gregory T. Everson and Neville Roy Pimstone and Jenny Donovan and Donald Albert},
  journal={Cytokines, cellular & molecular therapy},
  year={1999},
  volume={5 4},
  pages={207-10}
}
Hepatitis C virus (HCV) genotyping has been shown to predict response to interferon, but is expensive. HCV serotyping is less expensive and simpler, and may be similarly useful. Using data from a large, randomized trial comparing consensus interferon (CIFN) and interferon alfa-2b (IFN alfa-2b) in patients with chronic HCV, we evaluated response rates based on HCV serotypes versus genotypes. Patients included in this analysis received subcutaneous injection of 9 microg CIFN (n = 232) or 3 MU IFN… CONTINUE READING